Spyre Therapeutics stock falls after $300M public offering, shares dip

Spyre Therapeutics said it had launched a $300 million underwritten public offering of common stock, and the announcement coincided with a roughly 2% decline in after-hours trading despite earlier intraday gains tied to positive SKYLINE trial results. The juxtaposition of clinical news and a capital raise drove short-term volatility in the shares.

According to market reports, Spyre will sell all shares in the offering and granted the underwriters a 30-day option to purchase up to an additional $45 million of stock at the public offering price, less underwriting discounts. Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI and Guggenheim Securities, LLC are acting as joint book-running managers, with LifeSci Capital LLC serving as a passive bookrunner. The company said the offering remains subject to market and other customary conditions.

Earlier in the trading day the stock had jumped after the company reported positive induction results from its SKYLINE study of SPY001 in patients with moderate-to-severe ulcerative colitis, a development that had driven significant buying interest. The subsequent offering announcement tempered those gains as investors weighed near-term dilution against longer-term clinical prospects.

From a market-structure perspective, equity raises by clinical-stage biotechs often aim to secure funding for ongoing and planned trials while extending cash runway. For Spyre, proceeds are expected to support the advancement of its pipeline, which includes extended half-life antibody programs targeting α4β7, TL1A and IL-23. Nonetheless, the immediate effect of fresh share issuance can be downward pressure on the stock as supply increases and earnings per share would be diluted upon conversion.

In the broader industry context, the combination of encouraging clinical readouts and simultaneous fundraising is a familiar pattern: positive data can improve access to the capital markets, but issuances following good news may limit short-term upside. Investors typically balance the therapeutic potential against the dilution and track how management prioritizes spending—clinical milestones, trial enrollment and regulatory interactions remain focal points.

Analysts and market participants will now watch for final terms of the offering, the exercise of the underwriter option, and management commentary on the intended use of proceeds. If Spyre can translate SKYLINE results into sustained clinical momentum and demonstrate efficient use of capital, sentiment could recover; conversely, larger-than-expected dilution or disappointing follow-on data would likely keep pressure on the share price in the near term.